Perspectives on the clinical use of anti‐amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology

Abstract

Abstract Introduction The advent of disease‐modifying therapies for Alzheimer's disease (AD) has raised many questions and debates in the field as to the clinical benefits, risks, and costs of such therapies. The controversies have resulted in the perception that many clinicians are apprehensive about prescribing these medications to their patient populations. There also remains widespread uncertainty as to the economic impact, cost benefit ratio, and safety oversight for use of these medications in standard clinical care settings. Methods To contextualize such issues, the present study compared anti‐amyloid biologic therapy (lecanemab) to four commonly used biologic agents in other fields, including trastuzumab for breast cancer, bevacizumab for lung cancer, etanercept for rheumatoid arthritis, and ocrelizumab for multiple sclerosis. Results The data presented demonstrate comparable costs, clinical benefits, and risks for these biologic agents in their disparate disease states. Discussion These results provide context for the costs, clinical benefits, and safety regarding the mainstream use of anti‐amyloid biologic agents for the prevention of cognitive loss. While the era of disease‐modifying therapies for AD is now in its infancy, there is an expectation that these discoveries will be followed by improved therapies and combination treatments leading to greater efficacy in ameliorating the clinical trajectory of AD. Highlights Anti‐amyloid therapy costs are comparable to other commonly used biologics. Anti‐amyloid therapy efficacy is comparable to other commonly used biologics. Anti‐amyloid therapy safety is compatible with other commonly used biologics.

Keywords

• Alzheimer's disease
• anti‐amyloid therapy
• biologic agents
• mild cognitive impairment